Zhou X, Wang H, Koles NL, Zhang A, Aronson NE. Leishmania infantum-chagasi activates SHP-1 and reduces NFAT5/ TonEBP activity in the mouse kidney inner medulla. Am J Physiol Renal Physiol 307: F516 -F524, 2014. First published July 2, 2014; doi:10.1152/ajprenal.00006.2014.-Visceral leishmaniasis patients have been reported to have a urine concentration defect. Concentration of urine by the renal inner medulla is essentially dependent on a transcription factor, NFAT5/TonEBP, because it activates expression of osmoprotective genes betaine/glycine transporter 1 (BGT1) and sodium/myo-inositol transporter (SMIT), and water channel aquaporin-2, all of which are imperative for concentrating urine. Leishmania parasites evade macrophage immune defenses by activating protein tyrosine phosphatases, among which SHP-1 is critical. We previously demonstrated that SHP-1 inhibits tonicity-dependent activation of NFAT5/TonEBP in HEK293 cells through screening a genome-wide small interfering (si) RNA library against phosphatases (Zhou X, Gallazzini M, Burg MB, Ferraris JD. Proc Natl Acad Sci USA 107: 7072-7077, 2010). We sought to examine whether Leishmania can activate SHP-1 and inhibit NFAT5/TonEBP activity in the renal inner medulla in a murine model of visceral leishmaniasis by injection of female BALB/c mice with a single intravenous dose of 5 ϫ 10 5 L. chagasi metacyclic promastigotes. We found that SHP-1 is expressed in the kidney inner medulla. L. chagasi activates SHP-1 with an increase in stimulatory phosphorylation of SHP-1-Y536 in the region. L. chagasi reduces expression of NFAT5/TonEBP mRNA and protein as well as expression of its targeted genes: BGT1, SMIT, and aquaporin-2. The culture supernatant from L. chagasi metacyclic promastigotes increases SHP-1 protein abundance and potently inhibits NFAT5 transcriptional activity in mIMCD3 cells. However, L. chagasi in our animal model has no significant effect on urinary concentration. We conclude that L. chagasi, most likely through its secreted virulence factors, activates SHP-1 and reduces NFAT5/ TonEBP gene expression, which leads to reduced NFAT5/TonEBP transcriptional activity in the kidney inner medulla. ERK1/2; urinary concentration; aquaporin-2; virulence factors; leishmaniasis VISCERAL LEISHMANIASIS (VL) is a disseminated infection transmitted by the bite of infected sand flies and caused by parasite species Leishmania infantum-chagasi (L. chagasi) and Leishmania donovani. It is estimated that one to two million people worldwide are VL infected, with ϳ500,000 new cases and 50,000 deaths each year, marking this as a parasitic disease with a high mortality rate second only to malaria (2). Macrophages are a first line of immune defense against Leishmania infection and paradoxically also one of the primary reservoirs of Leishmania. To survive and propagate inside the phagocytes, Leishmania subvert the signaling activation of macrophages by activating protein tyrosine phosphatases PTP1B, TC-PTP, and SHP-1, and other inhibitory pathways, among which SHP-1 is critical (28, 50). Activation of SHP-1 inhibits MAP kinase, JAK-STAT, TLR, and IFN-␥ pathways, which leads to reduction of the generation of reactive oxygen species and nitric oxide, thus inhibiting innate immune responses (28, 50).
ERK1/2; urinary concentration; aquaporin-2; virulence factors; leishmaniasis VISCERAL LEISHMANIASIS (VL) is a disseminated infection transmitted by the bite of infected sand flies and caused by parasite species Leishmania infantum-chagasi (L. chagasi) and Leishmania donovani. It is estimated that one to two million people worldwide are VL infected, with ϳ500,000 new cases and 50,000 deaths each year, marking this as a parasitic disease with a high mortality rate second only to malaria (2) . Macrophages are a first line of immune defense against Leishmania infection and paradoxically also one of the primary reservoirs of Leishmania. To survive and propagate inside the phagocytes, Leishmania subvert the signaling activation of macrophages by activating protein tyrosine phosphatases PTP1B, TC-PTP, and SHP-1, and other inhibitory pathways, among which SHP-1 is critical (28, 50) . Activation of SHP-1 inhibits MAP kinase, JAK-STAT, TLR, and IFN-␥ pathways, which leads to reduction of the generation of reactive oxygen species and nitric oxide, thus inhibiting innate immune responses (28, 50) .
Renal involvement during VL infection is described in both humans (13, 14, 31, 42, 43) and dogs (3, 12) . A majority of VL patients have a defect in concentrating urine (13, 32) . A urine concentration defect is also described in Brazilian cutaneous leishmaniasis patients (42, 43) . The kidney inner medulla plays an essential role in concentrating urine. Nuclear factor of activation of T cells 5 (NFAT5), also named tonicity-responsive enhancer binding protein (TonEBP), is the newest member of the Rel family of transcription factors. It is expressed in a variety of tissues and regulates an assortment of functions, including immune responses (6, 7, 20) , cardiac development (37) , atherosclerosis (23) , and ischemia-induced brain injury (36) . In the kidney inner medulla, NFAT5 is known for its activation of expression of osmoprotective genes such as betaine/glycine transporter 1 (BGT1) and sodium/myo-inositol transporter (SMIT) (9, 58) , and genes necessary for water traffic like aquaporin-2 (AQP2) (27, 30) , aquaporin-1 (29) , and urea transporters (27, 39) . These genes are essential for the renal inner medulla to concentrate urine, a primary mechanism to maintain body fluid balance. Through screening a genomewide phosphatase small interfering (si) RNA library, we previously demonstrated that SHP-1 inhibits hypertonicity-induced activation of NFAT5 in HEK293 cells (63) . These data raise questions concerning whether SHP-1 is expressed in the kidney inner medulla and Leishmania activate SHP-1 and inhibit NFAT5 in that region, leading to the clinically observed urine concentration defect. The present study addresses these questions in a murine model of L. chagasi VL.
MATERIALS AND METHODS

Parasites and Parasite Supernatant
L. chagasi (parasite strain generously provided by Dr. Mary E. Wilson, University of Iowa) was grown at 26°C in DMEM, supplemented with 20% heat-inactivated FBS serum (GIBCO), 25 mM HEPES, 50 M 2-mercaptoetanol, and 20 g/ml of gentamicin (60) or HOMEM (5). The parasite supernatant was obtained by centrifuging cultured metacyclic promastigotes (ϳ1.2 ϫ 10 7 /ml parasites between passage 4 and passage 19) at 3,500 rpm at room temperature for 10 min twice. The supernatant can be stored at 4°C for at least 1 wk without losing the inhibitory effect on NFAT5 transcriptional activity.
Animals and Animal Infection
BALB/c mice (female, 5 wk old), purchased from Jackson Laboratory, were handled according to the procedures approved by the Uniformed Services University Institutional Animal Care and Use Committee. The mice were treated with a single tail vein injection of PBS (control) or 5 ϫ 10 5 metacyclic promastigotes of L. chagasi for 4 wk before they were euthanized. Both kidney inner medullas including the papillas of each mouse were quickly dissected on ice. In some cases, the liver and kidney cortex were also used. Analyses of protein phosphorylation and abundance, mRNA abundance, and SHP-1 activity were performed under blinded conditions.
Limiting Dilution Assay
Limiting dilution culture was performed as described previously (8, 54) . Briefly, liver, spleen, and kidney inner medulla tissue was harvested aseptically and homogenized in HO-MEM containing 10% FCS (5). Five-fold serial dilutions were incubated at 26°C. After culturing for 17-19 days, the highest dilution yielding growth of viable L. chagasi promastigotes was determined using a phasecontrast microscope.
Immunohistochemistry
The whole kidney was fixed with 10% formalin in neutral buffer (Thermo Scientific) overnight and then paraffin embedded and sliced in the university histology laboratory. Immunohistochemistry was performed according to the procedures described in the Cell Signaling Technology website (http://www.cellsignal.com/common/content/ content.jsp?idϭihc-paraffin-signalstain). Briefly, tissues were deparaffinized and rehydrated with xylene, ethanol, and water sequentially. Antigen was unmasked by boiling slides in sodium citrate buffer, EDTA buffer, and then Tris-EDTA buffer. Nonspecific binding was blocked by incubation of slides with Odyssey Blocking Buffer at room temperature for 1 h. Slides were then incubated with a rabbit anti-SHP-1 antibody at a 1:50 dilution (SC-287, Santa Cruz Biotechnology) or with additional 50ϫ SHP-1 peptide (SC-287P, Santa Cruz Biotechnology), or with a rabbit anti-AQP-2 antibody (1:500 dilution) overnight at 4°C. The specific antibody binding was recognized by an Alexa Fluor 647-conjugated secondary anti-rabbit antibody and imaged with a confocal microscope (LSM710). The images from the inner medulla were captured with a ϫ63 lens, whereas the images from the cortex were taken with a ϫ40 lens, because they were too weak to be captured with the ϫ63 lens.
SHP-1 Activity Assay
The inner medullas were homogenized in 10 mM triethanolamine, pH 7.4, and 250 mM sucrose plus a protease inhibitor tablet (Roche). The homogenates were precleared with agarose beads-Protein A/G Plus (SC-2003, Santa Cruz Biotechnology)-conjugated rabbit IgG at 4°C for 45 min. SHP-1 was immunoprecipitated with the same type of beads-conjugated rabbit anti-SHP-1 (SC-287, Santa Cruz Biotechnology) at 4°C for 2 h. After the beads were washed three times with a buffer containing 20 mM HEPES, pH 7.4, 100 mM NaCl, and 0.1% ␤-mercaptoethanol, they were incubated with the same buffer plus 100 M phosphor-tyrosine peptide substrate (RRLIEDAEpYAARG, 12-217, Millipore) at 37°C for 60 min. The released inorganic phosphatate was recognized by the freshly mixed malachite green solution A and B (17-127, Millipore) and measured at A630 (44) .
SHP-1 activity is expressed by the readings at A630 normalized to immunoprecipitated SHP-1.
Western Blot Analysis
Tissues were homogenized in 10 mM triethanolamine, pH 7.4, and 250 mM sucrose plus a protease inhibitor tablet (Roche), 2.0 M NaF, and 2.0 M Na 3VO4. The protein concentrations in homogenates were measured with a BCA assay (Pierce). Protein samples (18 g/lane in most cases) were fractionated in Bolt 4 -12% Bis-Tris Plus gel and then transferred to nitrocellulose membranes (Invitrogen) according to the manufacturer's protocol. The membranes were first blocked with Odyssey Blocking Buffer for 60 min at room temperature (Li-Cor) and then incubated with primary antibodies overnight at 4°C. The antibodies against ERK1/2-P, ERK1/2, STAT3-Y705-P, STAT3, AKT-S473-P, AKT1, GSK-3␤-S9-P, GSK-3␤, and GAPDH were purchased from Cell Signaling Technology (catalog nos. 9101, 9102, 9145, 4904, 4060, 2920, 9336, 9315, and 2118, respectively). The anti-SHP-1 and actin antibodies were purchased from Santa Cruz Biotechnology (catalog nos. SC-287 and SC-1615, respectively). The antibodies against SHP-1-Y536-P and SHP-1-S591-P were purchased from ECM Biosciences (catalog nos. SP-1571 and SP-1531, respectively). The anti-AQP2 antibody is a generous gift of Dr. Mark A. Knepper (National Heart, Lung, and Blood Institute). After incubation with primary antibodies and a brief wash with PBS plus 0.1% Tween 20, the membranes were incubated with Alexa Fluor-conjugated secondary antibodies at room temperature for 60 min. Protein expression and phosphorylation were analyzed by an Odyssey Infrared Imager (Li-Cor).
Quantitative PCR
Tissues were sonicated in an ice-cold RNAzol RT kit (Molecular Research Center). Total RNA was measured by NanoDrop 8000 (Thermo Scientific). cDNAs were synthesized with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). mRNAs were quantified with a SYBR Green PCR kit (QuantiFast, Qiagen) in Applied Biosystems 7900HT. The primers for each gene are listed in Table 1 . These primers were designed with a GenScrip online program. Two hundred nanograms total inner medulla RNA/reaction was used. 18S rRNA was used to control for the amount of cDNA used in each analysis, but mRNA abundance was not normalized to 18S rRNA. 18S rRNA primers and probes were purchased from Applied Biosystems. Fold-difference in mRNA abundance between conditions was calculated, as described previously (17) .
Cell Culture, Cell Transfection, and Luciferase Activity Assay mIMCD3 cells (47) were cultured in DMEM plus 10% FBS at 37°C supplemented with 5% CO 2-95% air and used between passage 14 and 24. The osmotic response element (ORE), which is the NFAT5-targeted DNA sequence luciferase reporter, and the mutated ORE luciferase reporter, in which the ORE was mutated to prevent NFAT5 binding, were described previously (62) . The reporter plasmids were transfected into mIMCD3 cells with Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol for 48 h. Then, Table 1 . List of primers
the cells were selected with 10 g/ml blasticidin and maintained with 5 g/ml of the antibiotic. The population of the stable cells without subcloning was used between passage 15 and 25. The stable cells expressing the ORE reporter or mutated ORE reporter and mIMCD3 cells were plated at subconfluence for 22 h and then treated with either the DMEM used for culturing L. chagasi or with the parasite supernatant for an additional 22 h before samples were collected. mIMCD3 cells were collected with M-PER buffer (Pierce) plus a protease inhibitor tablet (Roche), 2.0 M NaF, and 2.0 M Na 3VO4. The stable cells were collected in Bright-Glo lysis buffer (Promega). The osmolality of the medium and supernatant was raised to 500 mosmol/ kgH 2O by adding NaCl beefore treatments. The luciferase activity was measured by Bright-Glo (Promega) reagent and normalized by the protein content, which was measured by the BCA method.
Urinary Concentration Assay
After mice were infected with L. chagasi or injected with PBS (control) for 4 wk, they were placed in metabolic cages (Hatteras Instruments) and acclimated to a water-replete gelled food diet containing 4 g powdered food (OpenSource Diet), 0.09 g agar, and 5 ml water·20 g body wt Ϫ1 ·24 h Ϫ1 (61) for 48 h. Subsequently, the 24-h urine samples were collected with the same diet and same ration. Then, mice were fed with the water-restricted food diet of 4 g powdered food, 0.05 g agar, and 1 ml water·20 g body wt Ϫ1 ·24 h Ϫ1 for 24 h (61). Urine samples were collected under mineral oil. Mice were weighed before and after water restriction.
Statistical Analysis
Results are expressed as means Ϯ SE. The reading from the first mouse in the control group was set to one, and all other results were normalized to that value. Statistical analyses were performed by a nonpaired t-test (animal studies) or paired t-test (cell culture studies). P Յ 0.05 is considered significant.
RESULTS
SHP-1 Is Expressed in the Renal Inner Medulla
As the first step in studying the possible effect of SHP-1 on NFAT5 in the kidney inner medulla, we demonstrate that SHP-1 is expressed in the inner medulla, with high expression in the collecting duct epithelial cells (Fig. 1A) , as supported by immunohistochemical staining of AQP2, a specific marker of the collecting duct (Fig. 1D) . SHP-1 is also expressed in the renal cortex (Fig. 1E) . In contrast to the concentrated expression in the basolateral pericytoplasmic area of the inner medulla, expression of SHP-1 in the cortex is diffusive.
L. chagasi Infected BALB/c Mice
Limiting dilution assays of the liver and spleen show that mice were successfully infected with L. chagasi ( Table 2 ). The parasite was not detectable in the kidney by limiting dilution assay, Leishmania quantitative PCR of the inner medulla, or upon expert review of hematoxylin-and eosinstained renal histopathology slides (data not shown). Review of renal hematoxylin-and eosin-stained slides did not show any histological changes in the infected vs. control mice (data not shown).
L. chagasi Activates SHP-1 in the Kidney Inner Medulla
We found that L. chagasi increases SHP-1 activity in the inner medulla ( Fig. 2A) . As an additional test, we examined the phosphorylation of ERK1/2, which has been shown to be a regulatory target of SHP-1 in experimental visceral leishmaniasis (19) as well as in nonleishmaniasis models (55) , and phosphorylation of STAT3-Y705, which is dephosphorylated by SHP-1 in other models (38, 57) , but has not been demon- Fig. 1 . SHP-1 is expressed in the female BALB/c mouse kidney inner medulla and cortex. The SHP-1 antibody from rabbits was used at 1:50 dilution. The SHP-1 antibody competition binding assay was performed in the presence of 50ϫ SHP-1 peptide. The rabbit anti-aquaporin-2 (AQP2) antibody was used at 1:500 dilution. 
Values are means Ϯ S⌭. strated in leishmaniasis. We found that L. chagasi significantly reduces ERK1/2-P (Fig. 2B ) but has no significant effect on STAT3-Y705-P (Fig. 2C) . It is not clear how the parasite reduces ERK1/2 and STAT3 protein abundance (Fig. 2, B and C). The parasite does not increase macrophage infiltration to the region as measured by mRNA abundance of the phagocyte marker F4/80 and CD11b (Fig. 2D) , excluding the secondary effect of phagocytes.
L. chagasi Increases Phosphorylation of SHP-1-Y536 in the Kidney Inner Medulla and Cortex
The activity of SHP-1 is regulated by phosphorylation of its C terminus. Phosphorylation of the tyrosines, such as Y536, usually activates the phosphatase, whereas phosphorylation of the S591 often does the opposite (46) . We observed that L. chagasi significantly increases phosphorylation of SHP-1-Y536 (SHP-1-Y536-P) in the renal inner medulla (Fig. 3A) , whereas it has no significant effect on SHP-1-S591-P (Fig. 3B) . To determine whether the effect of L. chagasi on SHP-1-Y536-P is unique to the inner medulla or generalized, we examined the effect of the parasite on SHP-1-Y536-P in the renal cortex and found a similar effect (Fig. 3C) . We also found that expression of SHP-1 in the cortex is much more variable than that in the inner medulla, in addition to its diffusive pattern (Fig. 1E) . We conclude that L. chagasi increases SHP-1-Y536-P in the renal inner medulla and cortex, suggest- ing that the parasite activates SHP-1 through increasing SHP-1-Y536-P.
L. chagasi Reduces Expression of NFAT5 Gene and NFAT5-Targeted Genes in the Kidney Inner Medulla
L. chagasi significantly reduces mRNA and protein abundance of NFAT5 in the inner medulla (Fig. 4A) . L. chagasi also significantly reduces mRNA abundance of NFAT5-targeted genes BGT1, SMIT, and AQP2 and protein abundance of AQP2 (Fig. 4, B and C) . We could not examine the effect of the parasite on protein abundance of BGT1 or SMIT, because we did not find a satisfactory antibody against either of them. We conclude that L. chagasi inhibits NFAT5 transcriptional activity in the inner medulla.
The L. chagasi Supernatant Increases SHP-1 Protein Abundance and Inhibits NFAT5 Transcriptional Activity in mIMCD3 Cells
The failure to detect parasites in the kidney led us to examine whether L. chagasi activates SHP-1 and inhibits NFAT5 activity through its secreted virulence factors. We found that the supernatant from culturing the parasite significantly increases SHP-1 protein abundance by 48% and has no significant effect on SHP-1-S591-P (Fig. 5, A and B) . We could not detect SHP-1-Y536-P with the antibody either from ECM Bioscience or from Abcam (data not shown). The supernatant reduces the ORE luciferase reporter activity by 75%. In contrast, the supernatant only reduces the mutated ORE reporter activity by 22%, and the effect does not reach statistical significance (Fig. 5C) , indicating that the supernatant inhibits NFAT5 transcriptional activity through a specific mechanism. The supernatant has no significant effect on NFAT5 protein abundance (Fig. 5, A and C) . In contrast to the effect of L. chagasi in the kidney, the supernatant increases ERK1/2-P. However, the result cannot be semiquantified, because the ERK1/2-P signal in some cells treated with the DMEM culture medium is too weak to be read reliably (Fig. 5A) . We conclude that the L. chagasi culture supernatant inhibits NFAT5 transcriptional activity associated with an increase in the SHP-1 protein level in mIMCD3 cells.
L. chagasi Has No Significant Effect on AKT1-S471-P or GSK-3␤-S9-P in the Kidney Inner Medulla
The effects of L. chagasi on SHP-1 and NFAT5 prompted us to examine whether the parasite also affected other signaling pathways that have been demonstrated to regulate NFAT5 under hypertonic conditions. We chose AKT1 and GSK-3␤, because they are reported to have a role in leishmaniasis (40, 41) in addition to regulation of tonicity-dependent activation of NFAT5, and AKT1 phosphorylates GSK-3␤-S9 in the hypertonic context and in Leishmania infection (40, 65) . Phosphorylation of AKT1-S471 activates AKT1, whereas phosphorylation of GSK-3␤ serine 9 inhibits GSK-3␤. We found that L. chagasi has no significant effect on AKT1-S471-P or GSK-3␤-S9-P in the renal inner medulla (Fig. 6 ).
Intravenous Injection of 5 ϫ 10 5 Metacyclic Parasites/Mouse Does Not Induce a Urinary Concentration Defect
We found that infection of mice with 5 ϫ 10 5 parasites/ mouse does not significantly reduce urinary osmolality when mice were fed with a water-replete diet (control) or waterrestricted diet for 24 h (Fig. 7) . Water restriction does not significantly reduce body weight (control: from 19.3 Ϯ 0.4 to 19.8 Ϯ 0.4 g; infected: from 19.8 Ϯ 0.4 to 19.2 Ϯ 0.5 g). We conclude that L. chagasi at the dose we used has no significant effect on urinary concentration.
DISCUSSION
L. chagasi Activates SHP-1 in the Kidney Inner Medulla
Pathogens often exploit host signaling pathways to propagate their infection, because the signaling pathways regulate many host cellular defense processes (1) . Leishmania activate SHP-1 in host macrophages, which in turn inhibit activation of the macrophage immune defense response. The parasites achieve this effect through their secreted virulence factors such as EF-1␣, fructose-1,6-bisphosphate aldolase, and GP63 (28, 50) . Activation of an enzyme may be accompanied by an increase in its abundance or by a structural change either at the primary, secondary, or tertiary level or at all of these three levels. However, the intramolecular mechanisms by which Leishmania activate SHP-1 remains unknown. We have shown that L. chagasi significantly increases SHP-1 activity ( Fig. 2A) , which is associated with an increase in activational SHP-1-Y536-P (46) (Fig. 3A) and has no significant effect on inhibitory SHP-1-S591-P (46) (Fig. 3B ). The latter effect is different from the effect of hypertonicity, which inhibits SHP-1 function by increasing SHP-1-S591-P (64). Phosphorylation of Y536 activates SHP-1 possibly by releasing its autoinhibition (46) and increasing the affinity to its substrates (25) .
Most of our knowledge of the effect of Leishmania on SHP-1 comes from macrophage cell line models. L. major and L. mexicana activate SHP-1 by cleaving it in a murine macrophage cell line B10R cells (21, 24) . L. donovani increases SHP-1 protein abundance in another murine macrophage cell line, RAW264.7 (4). In the present study, we show that the L. chagasi supernatant also increases SHP-1 protein abundance in mIMCD3 cells (Fig. 5, A and B) , a mouse inner medullary collecting duct cell line (47) . However, we did not observe a significant effect of L. chagasi on SHP-1 protein abundance in the inner medulla or in the cortex (Fig. 3) . Besides the differences in Leishmania species and cell types, the duration and route of infection may also play an important role in how SHP-1 is activated. We intravenously infected mice with a single parasite dose and evaluated after 4 wk of infection, whereas in previous reports Leishmania were incubated in vitro with macrophage cell lines for hours and the cells were analyzed within days (4, 21, 24 ). In our cell culture studies, we also treated mIMCD3 cells with the supernatant only for 22 h. The difference between treatment of cells in vitro and infection of mice in vivo may also explain the different effects on NFAT5 protein abundance and ERK1/2-P observed in mIMCD3 cells and the kidney inner medulla (Figs. 2B, 4A, and  5, A and C) . However, our in vivo model is more representative of leishmaniasis in patients than in vitro infection of cell lines. From this model, we demonstrate for the first time that in addition to macrophages, L. chagasi also activates the enzyme SHP-1 in nonphagocytes as well (Fig. 2A) . Although SHP-1 is expressed abundantly in immune cells and inhibits immune responses in general (11) , it is also expressed in other cells and tissues and regulates various functions like cell growth, cell injury, and glucose homeostasis (15, 22, 34) . Therefore, besides subverting macrophage innate immune defense, SHP-1 could also be involved in Leishmania-induced pathological effects in nonphagocytic cells and tissues.
L. chagasi Inhibits NFAT5 in the Kidney Inner Medulla
A majority of NFAT5 homozygous knockouts are embryonically lethal (33) . Knockout of NFAT5 through multiple breeding procedures was associated with 20-fold increases in L. major parasite burden and splenic dissemination in a mouse species where L. major usually causes localized infection (10) . These data suggest that NFAT5 is protective against Leishmania infections and that Leishmania inhibit NFAT5 to propagate in the host. We speculate that NFAT5 could show protection against other parasitic or intracellular infections. Our present studies show that L. chagasi decreases NFAT5 mRNA and protein abundance in the kidney inner medulla (Fig. 4A ). This effect leads to a decrease in expression of its targeted genes, BGT1, SMIT, and AQP2, (Fig. 4 , B and C) and is associated with activation of SHP-1 ( Fig. 2A) . Furthermore, the L. chagasi A and B) . SHP-1-Y536-P was not detectable (data not shown). The supernatant has no significant effect on NFAT5 protein abundance (A and C) and increases ERK1/2-P (A). The supernatant inhibits NFAT5 transcriptional activity (C). mIMCD3 cells or mIMCD3 cells stably expressing the osmotic response element (ORE) or mutated ORE luciferase reporter were plated at subconfluence for 22 h, then treated with DMEM for culturing the parasite or supernatant for an additional 22 h, before collection for analyses. The cells remained subconfluent at the end of experiments. The DMEM and supernatant were raised to 500 mosmol/ kgH2O before they were used for treating cells. *P Ͻ 0.05, **P Ͻ 0.01 vs. the group treated with DMEM (control); n ϭ 4. culture supernatant inhibits NFAT5 transcriptional activity accompanied by an increase in SHP-1 protein level in mIMCD3 cells (Fig. 5) . SHP-1 is a signaling molecule, not a "housekeeping" gene. The presence of SHP-1 in the inner medulla raises a question as to what function this phosphatase might have. SHP-1 inhibits tonicity-dependent activation of NFAT5 in cell culture (63) . Our observations suggest that SHP-1 may inhibit NFAT5 in the inner medulla. Since the optimal function of NFAT5 is essential for the inner medulla to concentrate urine effectively, L. chagasi-induced inhibition of NFAT5 (potentially through the activation of SHP-1) may explain the urine concentration defect observed in Ͼ60% of patients with visceral leishmaniasis (13, 32) .
Effects of L. chagasi on Other Kinases and STAT3
Hypertonicity activates NFAT5 through multiple pathways (64, 65) . This prompted us to examine whether L. chagasi also affects other kinases such as ERK1/2, AKT1, and GSK-3␤, which have been demonstrated to regulate tonicity-dependent activation of NFAT5 (48, 56, 65) in the kidney inner medulla. Both increases and decreases in stimulatory ERK1/2-P have been observed in experimental visceral leishmaniasis, depending on the cell type and other experimental conditions (19, 41) . We found that L. chagasi reduces stimulatory ERK1/2-P in the kidney inner medulla (Fig. 2B) , but the L. chagasi supernatant increases ERK1/2-P despite its inhibition of NFAT5 transcriptional activity in mIMCD3 cells. L. chagasi has a tendency to reduce stimulatory AKT1-S473-P and inhibitory GSK-3␤-S9-P (Fig. 5) in the inner medulla, but the effects did not reach statistical significance, because of variations among mice (Fig.  5) . L. chagasi significantly reduces protein abundance of ERK1/2 ( Fig. 2A) , GSK-3␤ (Fig. 5B), and STAT3 (Fig. 2C) . A related species, L. donovani, induces proteasome-mediated degradation of STAT1␣ in the B10R macrophage cell line, and this effect is independent of SHP-1, but involves PKC␣ (18) . It should be noted that the parasite has no significant effect on STAT3 protein stability in the same study (18) . Whether L. chagasi-induced decreases in protein abundance of ERK1/2, GSK-3␤, and STAT3 are due to enhanced proteasome degradation remains to be studied. Nevertheless, it remains possible that L. chagasi inhibits NFAT5 through additional signaling pathways.
Possible Explanations for Lack of Effect of L. chagasi on Urinary Concentration Ability
In contrast to the potent inhibition of NFAT5 transcriptional activity by the L. chagasi supernatant from 1.2 ϫ 10 7 /ml metacyclics in mIMCD3 cells, infection of mice with 5 ϫ 10 5 promastigotes/mouse only modestly inhibited expression of NFAT5-targeted genes and did not cause a defect in urinary concentration. One of the possible reasons may be due to the fact that the dose of parasites we used was 2-20 times lower than what other investigators have reported (49, 59) . Another possible explanation is the genetic differences between humans and mice. Visceral leishmaniasis patients often die if they are left untreated, and the infection is chronic and progressive for months to years (53) . In contrast, BALB/c mice, which are more susceptible to Leishmania than C57BL/6 mice, will eventually resolve L. chagasi infection themselves (26) .
Perspective
We have demonstrated that L. chagasi activates SHP-1 and inhibits NFAT5 activity in the kidney inner medulla in our murine VL model (Fig. 4) . However, we did not find evidence that L. chagasi is present in the inner medulla. This raises a question as to how the parasite activates SHP-1 there. Leishmania secrete a large repertoire of molecules into the medium (24, 51) . It has been proposed that Leishmania activate SHP-1 through their secreted virulence factors (28, 50) . We speculate that L. chagasi may activate SHP-1 in the kidney inner medulla through the same mechanism. This speculation is supported by the observation showing that the L. chagasi culture supernatant increases SHP-1 protein abundance and reduces NFAT5 transcriptional activity in cultured mIMCD3 cells (Fig. 5) . Patients with Brazilian cutaneous Leishmaniasis have a urine concentration defect (43) . Injection of desmopressin did not raise urine osmolality, suggesting that urine concentration impairment is nephrogenic (43) . Since cutaneous Leishmaniasis is a localized infection, it is intriguing whether the Leishmania strains in these patients impair urinary concentration also through their secreted virulence factors.
SHP-1 is often regulated by membrane receptors for cytokines, growth factors, and antigens (11) . It is possible that mammals might have the endogenous membrane receptors for circulating Leishmania virulence factors, and the virulence factors bind these receptors, leading to activation of SHP-1. For example, Toll-like receptor 4 is an endogenous receptor for Gram-negative bacterial lipopolysaccharides (45) . Leishmania activates Toll-like receptor 2, 4, and other Toll-like receptors. However, activation of these Toll-like receptors leads to a reduction in parasite burdens (10, 16) , making these Toll-like receptors unlikely candidates for the receptors that link to activation of SHP-1, which promotes Leishmania propagation. Therefore, the identity of the endogenous membrane receptors for Leishmania circulating virulence factors remains to be defined.
In summary, SHP-1 is abundantly expressed in hematopoietic cells and has been studied extensively in these cells (35, Fig. 7 . L. chagasi infection in our model has no significant effect on urinary concentration. Mice were treated in the same way as in Fig. 2 . Mice were on a water-replete diet (control diet) in metabolic cages for 3 days. The last 24-h urine was collected for measuring basal urinary osmolality. Then, mice were switched to a water-restricted diet for 24 h and urine samples were collected (n ϭ 5).
52). We demonstrate that SHP-1 is also expressed in the cells of the renal inner medulla (Fig. 1) and that L. chagasi activates SHP-1 possibly through increasing phosphorylation of its Y536 in that region ( Figs. 2A and 3A) . This effect is not contributed to by macrophages, because L. chagasi does not increase macrophage infiltration to the inner medulla (Fig. 2D) . The L. chagasi culture supernatant increases SHP-1 protein abundance and inhibits NFAT5 transcriptional activity in mIMCD3 cells (Fig. 5) . L. chagasi, most likely through its secreted virulence factors, inhibits NFAT5 gene expression, which leads to reduced expression of NFAT5-targeted genes in the kidney inner medulla (Fig. 4) .
